Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation
Authors
Keywords
-
Journal
BLOOD
Volume 120, Issue 2, Pages 386-394
Publisher
American Society of Hematology
Online
2012-05-25
DOI
10.1182/blood-2011-12-399667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis
- (2011) Fu-Sheng Chou et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- How I treat acute myeloid leukemia
- (2010) J. M. Rowe et al. BLOOD
- A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study
- (2010) S. Miyawaki et al. BLOOD
- A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors
- (2010) A. Kellum et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics, Platelet Response, and Safety of Eltrombopag at Supratherapeutic Doses of up to 200 mg Once Daily in Healthy Volunteers
- (2010) Gemma Matthys et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia
- (2010) Celine Callens et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag
- (2010) Connie L. Erickson-Miller et al. LEUKEMIA RESEARCH
- Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome
- (2010) Irene Mavroudi et al. LEUKEMIA RESEARCH
- A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells
- (2009) A. Kalota et al. BLOOD
- Differentiation therapy of leukemia: 3 decades of development
- (2009) D. Nowak et al. BLOOD
- Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome
- (2009) B. Will et al. BLOOD
- The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase II in Breast Cancer Cells
- (2009) V. A. Rao et al. CANCER RESEARCH
- Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studies
- (2009) Daphne D. Williams et al. CLINICAL THERAPEUTICS
- Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
- (2009) Hagop Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
- (2008) Connie L. Erickson-Miller et al. STEM CELLS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now